FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

FSD Pharma Inc., a biopharmaceutical company dedicated to innovative solutions for neurodegenerative, inflammatory, and metabolic disorders, has released the outcomes of its annual general and special meeting of shareholders held on June 29, 2023.

During the meeting, there were 148 shareholders present or represented by proxy. The voting shares included 48 Class A multiple voting shares and 8,176,402 Class B subordinate voting shares. These shares accounted for approximately 66.67% and 20.94% of the votes attached to their respective share classes.

The election of directors resulted in the following votes:

Anthony Durkacz: Votes For - 21,442,510 (99.94%)
Zeeshan Saeed: Votes For - 21

'Pharmacology > BS' 카테고리의 다른 글

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate (0)	2023.07.02
Osemitamab (TST001) plus CAPOX as the First-Line Treatment of Advanced G/GEJ Cancer – Updated Efficacy Data per Claudin 18.2 Expression Level from Study TranStar102/TST001-1002-Cohort C (0)	2023.07.02
Study Shows DecisionDx-Melanoma Provides Prognostic Information on Survival Outcomes (0)	2023.07.02
New Dosing Schedule for Ropeginterferon Alfa-2b Shows Improved Efficacy in Polycythemia Vera (0)	2023.07.02
Delta-Fly Pharma Inc. Provides Schedule for Interim Analysis of Phase 3 Study of DFP-10917 in R/R AML (0)	2023.07.02

'Pharmacology > BS' 카테고리의 다른 글

티스토리툴바